Five-year covenant "Innovation and mutual trust" Novartis brings a number of blockbuster innovative products and industry-leading products

Shanghai, November 5, 2022 – Novartis today unveiled a number of recognized innovations, including the "world's only" or "world's first" for critical diseases, an industry-leading pipeline of product candidates, and advanced therapies at the 5th China International Import Expo, highlighting Novartis' efforts to expand access to medicine and the impact it will have on Chinese society
.

At this year's CIIE, Novartis focused on displaying a number of innovative drugs for cardiovascular, immunological, oncology, ophthalmology, central nervous system and other core therapeutic fields, including Noxinto, Keshanting ® ®, Nordage ®, Zhaole ®, Gleevec ® and other blockbuster products
that won the Galen Award.
The Galen Prize is the highest award in the medical community, also known as the "Nobel Prize in Medicine"
.
Since 1999, Novartis has received more than 50 Galen Awards, covering major diseases such
as cardiovascular, immunological, hematology, ophthalmology, and pico.

Novartis also showcased the world's leading pipeline and advanced therapies, including five technology platforms
: chemotherapy, biologics, xRNA, radioligand, and gene and cell therapies.
Novartis is the only company
to invest in R&D on all five technology platforms simultaneously.
Novartis currently has more than 100 ongoing research projects in China, covering a number of new drugs or indications
that will be developed and registered in China in the future.
Novartis expects to submit 50 applications for registration of new drugs or indications in China within five years
.

At this year's CIIE, Novartis also set up a "Mutual Trust" zone to demonstrate the far-reaching and lasting impact
of Novartis on Chinese society from four aspects: "expanding access to medicine and health, jointly building a standardized diagnosis and treatment system for key diseases, setting a model of sustainable development, and contributing to a healthy China".
From 2015 to 2021, more than 35 new drugs and indications have been approved in China, and Novartis' innovative drugs have benefited more than 20 million patients
in China.
Since 2017, more than 30 products from Novartis have been included in the national medical insurance catalogue
.

In addition, Novartis has worked with a number of medical institutions to build more than 4,000 standardized diagnosis and treatment centers, covering major high-incidence diseases such
as heart failure, ophthalmology and psoriasis.
In the Daliangshan area of Sichuan Province with an average altitude of 2,500 meters, Novartis has carried out a forestry carbon sink project spanning 30 years, planting about 21 million seedlings in total
.
As one of Novartis' four global "offsetting carbon footprint" projects, the project has brought multiple benefits
to the local community since its launch in 2010, including carbon reduction, biodiversity and poverty alleviation.

In addition, Novartis also set up a special interactive area on the booth of the Expo for major disease areas such as hyperlipidemia, breast cancer, fundus disease, psoriasis and ankylosing spondylitis, and held relevant popular science lectures to popularize related diseases and disease management knowledge
.

In recent years, the "spillover" effect of the Expo has been expanding, and Novartis has also
benefited.
With the highlight stage of CIIE, Novartis has established close ties with China's medical ecosystem, joining hands with Hainan Boao Lecheng and the Guangdong-Hong Kong-Macao Greater Bay Area to accelerate the introduction and implementation
of innovative drugs.
Up to now, Novartis has launched 6 overseas innovative special drugs in Boao Lecheng and 5 overseas innovative special drugs in the Guangdong-Hong Kong-Macao Greater Bay Area
.
At this year's CIIE, Novartis announced that it will continue to sign strategic cooperation agreements with a number of enterprises, governments and medical institutions to jointly improve medical standards, promote digital innovation, jointly build China's medical ecosystem, and contribute to the Healthy China strategy
.

Baednian, President of Novartis Group (China), said: "Novartis is an old friend of CIIE, and we fully support CIIE
.
CIIE provides a great opportunity
for us to showcase cutting-edge innovation and our efforts to deepen mutual trust and deepen our efforts with China.
I am looking forward to this year's CIIE and believe it will be a success
again.
”

Novartis is one of the
first multinational pharmaceutical companies to enter China.
We continue to focus on major and high-incidence disease areas to provide high-value, innovative medicines to patients in China, responding to China's growing and unmet medical needs
.
At present, China has become one of
Novartis' most important strategic markets in the world.
We will continue to uphold the concept of 'Rooted in China, Committed to China', deepen dialogue and cooperation with the local ecosystem, and promote long-term and sustainable development
.
" ”

Since participating in the first CIIE in 2018, Novartis has had about 20 innovative drugs and indications approved in China, many of which have been unveiled at CIIE before approval, and some are also domestic first
.

Novartis has 136 years of ties with China
.
Adhering to the concept of "Commitment to China, Deepening Mutual Trust, and Taking Root in China", Novartis is committed to working with all parties in China's healthcare ecosystem to promote and introduce innovation to bring health
to Chinese people.
Since 1987, Novartis has approved nearly 90 innovative drugs in China, ranking among the top
multinational pharmaceutical companies.

statement

1.
The purpose of this material is to convey cutting-edge information and research progress in medicine, and is not for advertising purposes
.

2.
The information contained in this material is for reference only, please follow the advice or guidance
of a doctor or other medical and health professional.